Piroxicam → Sudoxicam

HRID 1789158Notes

Reaction equation

[CH3:1][N:2]1[S:11](=[O:13])(=[O:12])[C:10]2[CH:9]=[CH:8][CH:7]=[CH:6][C:5]=2[C:4]([OH:14])=[C:3]1[C:15]([NH:17][C:18]1C=C[CH:21]=[CH:22][N:23]=1)=[O:16].CC1ON=C(NC(C2N(C)[S:41](=O)(=O)C3C=CC=CC=3C=2O)=O)C=1>>[OH:14][C:4]1[C:5]2[CH:6]=[CH:7][CH:8]=[CH:9][C:10]=2[S:11](=[O:13])(=[O:12])[N:2]([CH3:1])[C:3]=1[C:15]([NH:17][C:18]1[S:41][CH:21]=[CH:22][N:23]=1)=[O:16]

Participants

Reactant 2

HCID 54676228Piroxicam

HCID 54677972Isoxicam

Product 1

HCID 54682951Sudoxicam

Procedure

The oxicams may be combined with the special 1,2-diacyl-glycero-3-phosphocholines in a molar ratio of 1:1 to 1:20, preferably in a molar ratio of 1:1 to 1:10. A unit dose for the therapeutic application to humans amounts to 5-300 mg oxicam combined with 10-500 mg 1,2-diacyl-glycerol-3-phosphocholine per day, preferably 10-20 mg for piroxicam and 100-300 mg for isoxicam combined with 50-250 mg 1,1-diacyl-glycero-3-phosphocholine.

Sources & evidence

ORD record: ord-991606544acc4eb9b91f50e9dac2e1ee
Source dataset: uspto-grants-1987_08
DOI: 10.6084/m9.figshare.5104873.v1
Patent number: US04687766

Reaction notes

Loading…